Grail Picks Specific Method for Liquid Biopsy Clinical Trials

Discussion about the"Liquid Biopsy";"Liquid Biopsy" Used to Refer to Detection of Any Serum Cancer DNA). Initially, the test involved the isolation of circulating cancer cells from a blood sample, a daunting task due to their rarity, and the subsequent analysis of the DNA of them. Liquid biopsy research has evolved since then to the collection and analysis of cell-free circulating DNA and RNA. A recent article discussed howGrail, the apparent leader in the commercialization of the technology, has selected what it deems to be the best method for cancer detection in the blood (see:Grail, the liquid biopsy startup, picks an approach for its cancer test). Below is an excerpt from the article:Grail, the company that has raised $1.6 billion to develop a blood test to detect cancer early, announced Monday that it has settled on a method for its test and enrolled 115,000 patients in two large clinical trials. A third study, with 50,000 patients, has already begun. The San Francisco-based startup, spun out of DNA sequencing giantIllumina in 2016, previously presented data on three different approaches to detect cancer using DNA circulating in the blood.One used DNA sequencing to look at specific regions of genes; a second used the technology to sequence the entire genomes of cells floating in patients ’ bloodstreams; and a third looked atmethylation, an epigenetic change across the whole genome. Grail said in a statement that it has settled on the third method, w...
Source: Lab Soft News - Category: Laboratory Medicine Authors: Tags: Clinical Lab Industry News Clinical Lab Testing Diagnostics Food and Drug Administration Genomic Testing Healthcare Innovations Lab Industry Trends Lab Processes and Procedures Medical Research Predictive Analytics Preventive Medicine Source Type: blogs